WO2013062442A3 - Композиция для лечения рассеянного склероза (варианты) - Google Patents
Композиция для лечения рассеянного склероза (варианты) Download PDFInfo
- Publication number
- WO2013062442A3 WO2013062442A3 PCT/RU2012/000859 RU2012000859W WO2013062442A3 WO 2013062442 A3 WO2013062442 A3 WO 2013062442A3 RU 2012000859 W RU2012000859 W RU 2012000859W WO 2013062442 A3 WO2013062442 A3 WO 2013062442A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- multiple sclerosis
- variants
- treatment
- psychoneurology
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к области психоневрологии, в частности к средствам для лечения рассеянного склероза. Композиция (твердая оральная дозированная форма) содержит (Z)-2-циано-3-гидрокси-бут-2-эноик кислоты-(4'-трифторметилфенил)-амид (Терифлуномид) в качестве активного начала.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011143391 | 2011-10-27 | ||
RU2011143391/15A RU2471482C1 (ru) | 2011-10-27 | 2011-10-27 | Композиция для лечения рассеянного склероза (варианты) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013062442A2 WO2013062442A2 (ru) | 2013-05-02 |
WO2013062442A3 true WO2013062442A3 (ru) | 2013-06-27 |
Family
ID=48168742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2012/000859 WO2013062442A2 (ru) | 2011-10-27 | 2012-10-23 | Композиция для лечения рассеянного склероза (варианты) |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2471482C1 (ru) |
WO (1) | WO2013062442A2 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2536258C1 (ru) * | 2013-12-11 | 2014-12-20 | Ооо "Валента-Интеллект" | Способ получения таблеток терифлуномида |
WO2016189406A1 (en) | 2015-05-23 | 2016-12-01 | Ftf Pharma Private Limited | Pharmaceutical composition of teriflunomide |
WO2017037645A1 (en) * | 2015-09-02 | 2017-03-09 | Leiutis Pharmaceuticals Pvt Ltd | Stable pharmaceutical formulations of teriflunomide |
RU2638803C2 (ru) * | 2016-06-09 | 2017-12-15 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Таблетки биотина с замедленным высвобождением и способ их получения |
WO2017086835A1 (ru) * | 2015-11-17 | 2017-05-26 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты) |
WO2022085015A1 (en) * | 2020-10-24 | 2022-04-28 | V-Ensure Pharma Technologies Private Limited | A solid oral composition of teriflunomide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177623A1 (en) * | 2001-04-05 | 2002-11-28 | Joseph Wettstein | Use of (Z) -2-cyano-3-hydroxy-but-2-enoic acid-(4' -trifluoromethylphenyl)-amide for treating multiple sclerosis |
-
2011
- 2011-10-27 RU RU2011143391/15A patent/RU2471482C1/ru active
-
2012
- 2012-10-23 WO PCT/RU2012/000859 patent/WO2013062442A2/ru active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177623A1 (en) * | 2001-04-05 | 2002-11-28 | Joseph Wettstein | Use of (Z) -2-cyano-3-hydroxy-but-2-enoic acid-(4' -trifluoromethylphenyl)-amide for treating multiple sclerosis |
Non-Patent Citations (3)
Title |
---|
P. W. O'CONNOR ET AL.: "A Phase II study of the safety and afficacy of teriflunomide in multiple sclerosis with relapses.", NEUROLOGY, vol. 66, 2006, pages 894 - 900, XP002556504, DOI: doi:10.1212/01.WNL.0000203121.04509.31 * |
PAUL O'CONNOR ET AL.: "Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis.", N ENG J MED, vol. 356, 2011, pages 1293 - 1303, XP008144963 * |
V. . CHESHOV ET AL.: "Promyshlennaya tekhnologiya lekarst. Kharkov", IZDATELSTVO NFAU, 2002, pages 330 - 334, 352-355 * |
Also Published As
Publication number | Publication date |
---|---|
RU2471482C1 (ru) | 2013-01-10 |
WO2013062442A2 (ru) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013062442A3 (ru) | Композиция для лечения рассеянного склероза (варианты) | |
BR112014015568A8 (pt) | compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia | |
WO2013090278A3 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
NZ602557A (en) | Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2014120808A8 (en) | Pyridone amides as modulators of sodium channels | |
WO2010127099A3 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
MX363019B (es) | Composicion saborizante que comprende mentol y mentano-carboxamidas. | |
ZA201101278B (en) | Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies | |
SG191068A1 (en) | New form of administration of enkephalinase inhibitor | |
WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
CA2767833C (en) | N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen | |
MX2009012472A (es) | Combinacion que comprende acido pirrolidona-5-carboxilico y por lo menos un compuesto de citrulina, arginina y asparragina, y su uso en el tratamiento de dermatitis atopica. | |
WO2014102592A3 (en) | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof | |
AU2016216741A1 (en) | Compositions and methods of use of an inappetance-controlling compound | |
WO2012002773A3 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
WO2013087654A3 (en) | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation | |
MX2019012375A (es) | Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1). | |
MX2013002649A (es) | Agente terapeutico contra el dolor. | |
MA32480B1 (fr) | Compositions pédiatriques pour le traitement de la sclérose en plaques | |
EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения | |
BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12842793 Country of ref document: EP Kind code of ref document: A2 |